From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19

Research output: Contribution to journalArticlepeer-review

Abstract

We concisely review clinical, autopsy, experimental and molecular data of 2019 coronavirus disease (COVID-19). Angiotensin-converting enzyme 2 disruption and thromboinflammatory microangiopathy emerge as distinctive features. Briefly, entry of the virus into microvessels can profoundly disrupt the local renin-angiotensin system, cause endothelial injury, activate the complement cascade and induce powerful thromboinflammatory reactions, involving, in particular, von Willebrand factor, that, if widespread, may lead to microvascular plugging, ischemia and, ultimately, organ failure. We believe the current COVID-19 data consolidate a widely unrecognised paradigm of potentially fatal thromboinflammatory microvascular disease.

Original languageEnglish
Pages (from-to)243-247
Number of pages5
JournalInternational Journal of Cardiology
Volume326
DOIs
Publication statusPublished - Mar 1 2021

Keywords

  • 2019 coronavirus
  • Complement
  • Renin-angiotensin system
  • Thromboinflammatory microangiopathy
  • von Willebrand factor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19'. Together they form a unique fingerprint.

Cite this